

台灣癌症登記中心通知

急件

發件人： 台灣癌症登記中心
電話： 02-2341-6012
傳真： 02-2351-1733
地址： 100 台北郵政 84-310 信箱
日期： 105 年 1 月 6 日
編號： 癌登第 105001 號

收文者： 所有申報醫院

副本收文者： 衛生福利部國民健康署、台灣癌症登記學會、資拓宏宇國際股份有限公司

主 題： 因應105年癌症登記實務作業之需求及100年版台灣癌症登記摘錄手冊-104年修訂版使用說明，請 貴院依說明段辦理

急件 請檢閱 請加註 請回覆 請回收

- 一、 本案係依衛生福利部國民健康署委託「台灣癌症登記工作計畫」辦理。
- 二、 「100年版台灣癌症登記摘錄手冊」-104年修訂版及「癌症部位特定因子(SSF)編碼手冊」-104年修訂版，業由各醫院惠示意見並依據專家會議討論後修訂完竣，修訂版之附錄修訂處有詳細更新說明，提供醫院參考。完整修訂版檔案請逕至台灣癌症登記中心網站下載，網址如下：
<http://tcr.cph.ntu.edu.tw/main.php?Page=A6>。
- 三、 自105年起所有診斷年度個案，均全面採用上述104年修訂版申報。另103診斷年仍需申報個案，可沿用103年修訂版本申報，但必須於105年1月8日前依法完成申報。
- 四、 「100年版台灣癌症登記摘錄手冊」與「癌症部位特定因子(SSF)編碼手冊」-104年修訂版重要修正摘要如下，詳細內容請參考104年修訂版手冊：
 - (1) 原預計自104診斷年癌症個案，於台灣癌症登記長表摘錄手冊其他因子中新增「首次治療前生活功能狀態評估(Assessment of Performance Status before Treatment)」欄位，**決議不新增**，維持長表114欄位與短表42欄位。
 - (2) 直腸乙狀結腸、直腸癌 SSF9「直腸腫瘤下緣與肛門口的距離」：新增直腸乙狀結腸(Rectosigmoid junction, C199)個案為不適用(編碼988)。
 - (3) 肝癌 SSF3「Child Pugh 分數」：表格內"Prothrombin time prolonged, sec (INR) 凝血酶原時間"數值範圍修正。
- 五、 癌症登記摘錄編碼規則通知：
經癌症登記學會教育委員會共識決議，因 UFT/UFUR 屬複合式藥物(Tegafur+Uracil)，Tegafur 為 5-FU 的前驅物質(屬化學藥物)，Uracil 為核酸構成成份，作用在抑制將 5-FU 代謝(Uracil 非化學藥物)；故 UFT/UFUR 於「外院化學治療」與「申報醫院化學治療」欄位應登錄 02 只有一種化學藥物。

六、近年 WHO 新出版 bluebook 重要訊息摘錄如下，另附件提供新增 ICD-O-3 編碼與敘述係依據 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (2015)、WHO Classification of Tumours of Female Genital Organs (2014)、WHO Classification of Tumours of Soft Tissue and Bone (2013)與 WHO Classification of Tumours of the Breast (2012)彙整而成，因 2000 年出版之 ICD-O-3 編碼不敷使用，且現行病理報告按最新組織型態記載，故提供最新病理組織型態編碼供醫院使用。(附件更新自癌登 103012 號通知文內容)：

- (1) 依據 2015 年新出版 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart：胸腺瘤(Thymoma)個案若屬於下表內之組織型態者，自 **104 診斷年起**視為惡性腫瘤且依規定編碼申報。

病理報告描述	ICD-O-3 MOCDE
Type A thymoma, including atypical variant	8581/3
Type AB thymoma	8582/3
Type B1 thymoma	8583/3
Type B2 thymoma	8584/3
Type B3 thymoma	8585/3
Metaplastic thymoma	8580/3
Sclerosing thymoma	8580/3

- (2) 2015 年新出版 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart：原本 bluebook 編碼為 8250/2-Minimally invasive adenocarcinoma, Non-mucinous，與 8410/2-Adenocarcinoma in situ, Non-mucinous，經由台灣病理學會向 WHO 詢問後確認紙本為誤植，正確的編碼為 **8256/3-Minimally invasive adenocarcinoma, Non-mucinous**，與 **8250/2-Adenocarcinoma in situ, Non-mucinous**。
- (3) 依據上述第(2)點 2015 年新出版的 WHO bluebook：若肺癌組織型態為 Acinar adenocarcinoma，請編碼為 8551/3。
- (4) 依據 2013 年出版 WHO Classification of Tumours of Soft Tissue and Bone：組織型態編碼 Dermatofibrosarcoma protuberans (8832/1)與 Pigmented dermatofibrosarcoma protuberans (8833/1)，其性態碼已由 3(惡性)改為 1(不確定是否良性或惡性)，不用申報；若組織型態為 Fibrosarcomatous dermatofibrosarcoma protuberans (8832/3)，則須申報。
- (5) 依據 2012 年出版 WHO Classification of Tumours of the Breast：新增乳癌組織型態編碼 **Encapsulated papillary carcinoma (8504/2)**與 **Encapsulated papillary carcinoma with invasion (8504/3)**，因 ICD-O-3 至今尚未改版，原此類個案僅能借用甲狀腺癌組織型態編碼 **Papillary carcinoma, encapsulated (8343/3)**來進行申報，但自 103 年第四季起即可依新增編碼申報；另請注意此類型原位癌與侵襲癌的描述差異。

七、神經內分泌癌(Neuroendocrine Tumors, NETs)分級分化登錄規則：
 依據 The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems (Pancreas 2010;39:707-12) 與 AJCC 第七版 17 章節內容，並諮詢病理學會專家後整理如下：

	Code	Lung and Thymus	GastroEnteroPancreatic-NETs*
		WHO	ENETS, WHO
Grade			
Low grade	1	Carcinoid tumor 8240/3	NET Grade 1 (G1) 8240/3
Intermediate grade	2	Atypical carcinoid tumor 8249/3	NET Grade 2 (G2) 8249/3
High grade	3	Small cell carcinoma 8041/3 Large cell NEC 8013/3	NEC Grade 3 (G3), Small cell NEC 8041/3 NEC Grade 3 (G3), Large cell NEC 8013/3
Other subtypes			
	3	Combined small cell carcinoma 8045/3	
	*		EC cell, serotonin-producing NET 8241/3
	*		Enterochromaffin-like cell tumor, malignant 8242/3
	*		Goblet cell carcinoid 8243/3
	*		Mixed adenoneuroendocrine carcinoma 8244/3
	*		Adenocarcinoid tumor 8245/3
	*		Neuroendocrine carcinoma, NOS 8246/3
	*		Nonfunctional pancreatic NET, G1, G2 8150/3
	*		Insulinoma 8151/3
	*		Glucagonoma 8152/3
	*		Gastrin-producing NET (Gastrinoma) 8153/3
	*		Mixed islet cell & exocrine adenocarcinoma 8154/3
	*		VIPoma 8155/3
	*		Somatostatin-producing NET 8156/3

*消化道神經內分泌癌(包含特殊組織型態)需依據 mitotic count 及/或 ki-67 labeling index 來分級：

G1: mitotic count < 2 per 10 high power fields (HPF) AND < 3% Ki67 index;

G2: mitotic count 2–20 per 10 HPF OR 3–20% Ki67 index;

G3: mitotic count > 20 per 10 HPF OR > 20% Ki67 index

Status	ICD-O-3	Term
New code and term	8023/3	NUT carcinoma (C34._, C37.9)
New term	8044/3	Small cell carcinoma, hypercalcaemic type (C56.9)
New behavior code and term	8071/2	Differentiated-type vulvar intraepithelial neoplasia (C51._)
New term	8144/3	Enteric adenocarcinoma (C34._)
New term	8200/3	Thymic carcinoma with adenoid cystic carcinoma-like features (C37.9)
New behavior code and term	8250/2	Adenocarcinoma in situ, non-mucinous (C34._)
New term	8250/3	Lepidic adenocarcinoma (C34._)
New behavior code and term	8253/2	Adenocarcinoma in situ, mucinous (C34._)
New term	8253/3	Invasive mucinous adenocarcinoma (C34._)
New term	8254/3	Mixed invasive mucinous and non-mucinous adenocarcinoma (C34._)
New code and term	8256/3	Minimally invasive adenocarcinoma, non-mucinous (C34._)
New code and term	8257/3	Minimally invasive adenocarcinoma, mucinous (C34._)
New behavior code and term	8380/2	Atypical hyperplasia / Endometrioid intraepithelial neoplasia (C54._)
New behavior code and term	8441/2	Serous tubal intraepithelial carcinoma (C57.0)
New behavior code and term	8441/2	Serous endometrial intraepithelial carcinoma (C54._)
New behavior code and term	8460/2	Serous borderline tumour - micropapillary variant (C56.9)
New behavior code and term	8460/2	Non-invasive low-grade serous carcinoma (C56.9)
New term	8460/3	Low-grade serous carcinoma (C48._, C57._)
New term	8461/3	High-grade serous carcinoma (C48._, C57._)
New code and term	8474/3	Seromucinous carcinoma (C56.9)
New term	8500/3	Adenocarcinoma of mammary gland type (C51._)
New term	8504/2	Encapsulated papillary carcinoma (C50._)
New term	8504/3	Encapsulated papillary carcinoma with invasion (C50._)
New behavior code and term	8507/3	Invasive micropapillary carcinoma (C50._)
New code and term	8509/2	Solid papillary carcinoma in situ (C50._)
New code and term	8509/3	Solid papillary carcinoma invasive (C50._)

Status	ICD-O-3	Term
New code and term	8519/2	Pleomorphic lobular carcinoma in situ (C50.)
New term	8551/3	Acinar adenocarcinoma (C34.)
New term	8580/3	Metaplastic thymoma / Sclerosing thymoma (C37.9)
Behavior code change (1→3)	8581/3	Type A thymoma, including atypical variant (C37.9)
Behavior code change (1→3)	8582/3	Type AB thymoma (C37.9)
Behavior code change (1→3)	8583/3	Type B1 thymoma (C37.9)
Behavior code change (1→3)	8584/3	Type B2 thymoma (C37.9)
Behavior code change (1→3)	8585/3	Type B3 thymoma (C37.9)
New code and term	8714/3	Neoplasms with perivascular epithelioid cell differentiation (PEComa) NOS, malignant (C34., C47., C49., C54.)
New behavior code and term	8825/3	Low-grade myofibroblastic sarcoma (C47., C49.)
Behavior code change (3→1)	8832/1	Dermatofibrosarcoma protuberans (C47., C49.)
New term	8832/3	Fibrosarcomatous dermatofibrosarcoma protuberans (C47., C49.)
Behavior code change (3→1)	8833/1	Pigmented dermatofibrosarcoma protuberans (C47., C49.)
New term	8840/3	Low-grade fibromyxoid sarcoma (C47., C49.) Sclerosing epithelioid fibrosarcoma (C47., C49.)
New behavior code and term	8842/3	Pulmonary myxoid sarcoma with EWSR1-CREB1 translocation (C34.) Ossifying fibromyxoid tumour, malignant (C47., C49.)
New term	8936/3	Extra-gastrointestinal stromal tumour (C48.)
New term	8963/3	Extra-renal rhabdoid tumour (C47., C49.)
New behavior code and term	8983/3	Adenomyoepithelioma with carcinoma (C50.)
New term	9084/3	Germ cell tumours with sometic-type solid malignancy (C37.9)
New code and term	9086/3	Germ cell tumours with associated haematological malignancy (C37.9)
New code and term	9137/3	Pulmonary artery intimal sarcoma (C34.) Intimal sarcoma (C47., C49.)
New term	9180/3	Extraskeletal osteosarcoma (C47., C49.)
New term	9231/3	Extraskeletal myxoid chondrosarcoma (C47., C49.)
New code and term	9542/3	Epithelioid malignant peripheral nerve sheath tumour (C47., C49.)

說明：綠色網底表示為本次新增編碼與修訂敘述。